Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Ado-Trastuzumab Emtansine MeSH Descriptor Data 2026


MeSH Heading
Ado-Trastuzumab Emtansine
Tree Number(s)
D02.540.505.495.500
D04.345.295.500.500
D12.776.124.486.485.114.224.060.875.500
D12.776.124.790.651.114.224.060.875.500
D12.776.377.715.548.114.224.200.875.500
Unique ID
D000080044
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000080044
Scope Note
Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Entry Term(s)
Kadcyla
Trastuzumab Emtansine
Trastuzumab-DM1
Trastuzumab-DM1 Conjugate
huN901-DM1
Pharm Action
Immunotoxins
Tubulin Modulators
Antineoplastic Agents, Immunological
Registry Numbers
SE2KH7T06F
0
Public MeSH Note
2020; ADO-TRASTUZUMAB EMTANSINE was indexed under TRASTUZUMAB and MAYTANSINE 2012-2019 and under ANTIBODIES, MONOCLONAL 2010-2011
History Note
2020 (2010)
Date Introduced
2020/01/01
Last Updated
2020/01/01
Ado-Trastuzumab Emtansine Preferred
huN901-DM1 Narrower
Kadcyla Narrower
Trastuzumab-DM1 Conjugate Narrower
page delivered in 0.131s